Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757603 | 1.00 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL8857027 | 1.00 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL309710 | 1.00 | AKR1B1 (0.36) | AKR1B1 | |
| SCHEMBL5370601 | 0.81 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL5370609 | 0.81 | AKR1B1 (0.37) | AKR1B1 | |
| SCHEMBL310198 | 0.80 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL22692164 | 0.80 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL28258836 | 0.78 | AKR1B1 (0.39) | AKR1B1 | |
| SCHEMBL3749152 | 0.78 | AKR1B1 (0.39) | AKR1B1 | |
| SCHEMBL3239490 | 0.77 | AKR1B1 (0.37) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-04-19 | — | — | US | claimed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2006-02-02 | — | — | US | claimed |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2005-02-24 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117222433-A | Medicaments conjugated to hexose phosphate and methods of making and using the same | 密西西比州立大学 | 2023-12-12 | — | — | CN | disclosed |
| EP-4221755-A1 | DRUGS CONJUGATED WITH HEXOSE PHOSPHATE AND METHODS OF MAKING AND USING SAME | Mississippi State University (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2004111199-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS, WITH FATTY ACID METABOLISM INHIBITORS AND/OR GLYCOLYTIC INHIBITORS | UNIVERSITY OF COLORADO SYSTEM TECHNOLOGY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6670330-B1 | Treating human breast cancer | LAMPIDIS THEODORE J (US) | 2003-12-30 | — | — | US | disclosed |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | AKR1B1 924/4885 |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | AKR1B1 2102/4885 |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885 |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885 |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885 |
| US-20120094946-A1 | GLYCOSYLATED CHLORAMBUCIL ANALOGS AND USES THEREOF | CD22, UGGT1, UGCG | AKR1B1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.